Literature DB >> 9695979

IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood.

E Lindmark1, T Tenno, J Chen, A Siegbahn.   

Abstract

Interleukin 4 (IL-4), IL-10 and IL-13 are all known to modulate several proinflammatory functions in human monocytes. They have also previously been shown to down-regulate lipopolysaccharide (LPS)-induced tissue factor (TF) expression in isolated cultured monocytes. In this study we investigated the effect of these three cytokines on the induction of monocytic TF in a whole blood environment at three levels: mRNA quantitation, surface antigen expression and procoagulant activity. We showed that IL-10 attenuated LPS-induced monocyte TF expression and activity in whole blood in a concentration-dependent manner, both when added to the blood prior to LPS and, although to a lesser extent, when added up to 1 h subsequent to LPS challenge. Maximum inhibition occurred at 5 ng/ml of IL-10 when the cytokine was added before LPS. IL-4 and IL-13, however, did not exhibit any inhibitory effect in the whole blood environment, contrary to the reported findings in cell culture experiments. Our results confirm the potential of IL-10 as an anti-inflammatory, TF-preventing drug, whereas the effects of IL-4 and IL-13 on monocytes in whole blood seem more complex, and require further investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9695979     DOI: 10.1046/j.1365-2141.1998.00808.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Interleukin-10 regulates the tissue factor activity of monocytes in an in vitro model of bacterial endocarditis.

Authors:  M H Veltrop; J A Langermans; J Thompson; M J Bancsi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease.

Authors:  Gyeong-Im Yu; Ho-Chan Cho; Yun-Kyeong Cho; Hyoung-Seob Park; Hyuck-Jun Yoon; Hyung-Seop Kim; Chang-Wook Nam; Yoon-Nyun Kim; Kwon-Bae Kim; Eunyoung Ha; Dong-Hoon Shin; Seung-Ho Hur
Journal:  Inflamm Res       Date:  2012-05-17       Impact factor: 4.575

3.  Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion.

Authors:  Martin Weger; Iris Steinbrugger; Yosuf El-Shabrawi; Beate Julia Wegscheider; Wolfgang Weger; Wilfried Renner; Otto Schmut; Anton Haas
Journal:  Mol Vis       Date:  2007-04-04       Impact factor: 2.367

Review 4.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 5.  Monocyte/Macrophage-Mediated Innate Immunity in HIV-1 Infection: From Early Response to Late Dysregulation and Links to Cardiovascular Diseases Onset.

Authors:  Eman Teer; Danzil E Joseph; Richard H Glashoff; M Faadiel Essop
Journal:  Virol Sin       Date:  2021-01-05       Impact factor: 4.327

6.  Thrombomodulin phenotype of a distinct monocyte subtype is an independent prognostic marker for disseminated intravascular coagulation.

Authors:  Sang Mee Hwang; Ji-Eun Kim; Kyou-Sup Han; Hyun Kyung Kim
Journal:  Crit Care       Date:  2011-04-14       Impact factor: 9.097

7.  Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.

Authors:  Tomasz W Kamiński; Krystyna Pawlak; Małgorzata Karbowska; Michał Myśliwiec; Dariusz Pawlak
Journal:  BMC Nephrol       Date:  2017-01-25       Impact factor: 2.388

8.  Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome.

Authors:  A Mälarstig; P Eriksson; A Hamsten; B Lindahl; L Wallentin; A Siegbahn
Journal:  Heart       Date:  2007-08-09       Impact factor: 5.994

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.